检索结果-南通市图书馆

Plastic and Aesthetic Research 2015年第1期2卷 353-356页

作者： Laxmi kanta Mishra Sanjeev Gupta surya kanta pradhan Manas RBaisakh Department of Plastic Surgery Apollo HospitalsBhubaneswar 751005OrissaIndia Department of ENT-Head Neck Surgery Apollo HospitalsBhubaneswar 751005OrissaIndia Department of Pathology Apollo HospitalsBhubaneswar 751005OrissaIndia

Rhinosporidiosis is caused by the organism Rhinosporidium *** is a rare aquatic protistan *** more prevalent in Asiatic regions,cases have also been reported in European *** India,it mostly affects the southern *** seeberi most commonly affects the mucous membranes,but can also affect other structures including the larynx,trachea,skin,genitalia,lungs and *** typical presentation is that of a pinkish mass which bleeds *** lacrimal sac rhinosporidiosis is very *** tomography scans and magnetic resonance imaging are helpful in diagnosis,but histopathological study along with Gomori methenamine silver,periodic acid-Schiff,and potassium chloride are required for *** mainstay of treatment is *** is excellent,but recurrence is not unusual.

关键词： Computed tomography scan lacrimal sac Rhinosporidium seeberi rhinosporidiosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection

引用

World Journal of Experimental Medicine 2022年第3期12卷 44-52页

作者： Jyoti Bajpai Akshyaya pradhan Ajay Kumar Verma surya Kant Department of Respiratory Medicine King George's Medical UniversityLukcnowLucknow 226003Uttar PradeshIndia Department of Cardiology King George's Medical UniversityLukcnowLucknow 226003Uttar PradeshIndia Department of Respiratory Medicine King George Medical UniversityLucknow 226003Uttar PradeshIndia

Coronavirus disease 2019(COVID-19)infection is unequivocally the worst crisis in recent decades,which is caused by a severe acute respiratory virus ***,there is no effective therapy for the COVID-19 *** countries have different guidelines for treating COVID-19 in the absence of an approved therapy for ***,there is an imminent need to identify effective treatments,and several clinical trials have been conducted *** hydroxychloroquine[HCQS],chloroquine,and azithromycin(AZ)have been widely used for management based on in vitro studies favoring antiviral effects against the COVID-19 ***,there is evidence both in favor and against the use of hydroxychloroquine and azithromycin(HCQS+AZ)combination therapy to manage the COVID-19 *** combination of hydroxychloroquine and azithromycin was significantly associated with increased adverse ***,the inference of these findings was from observational ***,large randomized trials are imperative to show the future path for the use of HCQS+AZ combination ***,owing to the ban on HCQS use in COVID-19,this may no longer be *** review is on the pharmacology,trials,regimens,and side effects of hydroxychloroquine and azithromycin combination therapy.

关键词： Hydroxychloroquine Azithromycin Antiviral effects QT interval Randomized controlled trial

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Monoclonal antibody for COVID-19: Unveiling the recipe of a new cocktail

引用

World Journal of Respirology 2023年第1期12卷 1-9页

作者： Jyoti Bajpai surya Kant Ajay Kumar Verma Akshyaya pradhan Department ofRespiratory Medicine King George’s Medical UniversityLucknow 226003India Department ofCardiology King George’s Medical UniversityLucknow 226003India

The coronavirus disease 2019(COVID-19)pandemic has had a tremendous adverse impact on the global health system,public sector,and social *** is unarguably the worst pandemic of the ***,COVID-19 management is a mystery in front of us,and an authentic treatment is urgently *** repurposed drugs,like ivermectin,remdesivir,tocilizumab,baricitinib,etc.,have been used to treat COVID-19,but none are *** therapy and their combinations are emerging modalities for treating moderate COVID-19,and they have shown the potential to reduce *** antibody monotherapy,bamlanivimab,and two cocktails,casirivimab/imdevimab and bamlanivimab/esterivimab,have received authorization for emergency use by the United States Food and Drug Administration for the treatment of mild COVID-19 in high risk *** European Emergency has made similar recommendations for use of the drug in COVID-19 patients without oxygen *** brief review will focus on monoclonal antibodies and their combination cocktail therapy in managing COVID-19 infection.

关键词： SARS-CoV-2 Mild COVID-19 Antibodies Risk factors

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：